Table 1.
Patient characteristics
| Characteristics | N (%)/median (IQRa) |
|---|---|
| Gender | |
| Male | 112(91.1%) |
| Female | 11(8.9%) |
| Age | 58(47-64) |
| < 60 | 69(56.1%) |
| ≥60 | 54(43.1%) |
| Aetiology of liver disease | |
| Hepatitis B | 117(95.2%) |
| Hepatitis C | 3(2.4%) |
| Alcoholic cirrhosis | 3(2.4%) |
| BCLC classificationa | |
| A | 14(11.4%) |
| B | 27(22.0%) |
| C | 71(57.7%) |
| D | 11(8.9%) |
| PVTTa | |
| No | 43(35.0%) |
| Yes | 80(65.0%) |
| Number of tumors | |
| Single | 42(34.1%) |
| Multiple | 81(65.9%) |
| MELDa | 14.50(13.34-15.75) |
| <15 | 76(61.8%) |
| ≥15 | 47(38.2%) |
| Symptomatic portal hypertension | |
| Refractory ascites | 51(41.5%) |
| Variceal bleeding | 49(39.8%) |
| Both | 23(18.7%) |
| Refractory diarrhea | 5(4.1%) |
| Laboratory tests | |
| Platelets [109/L] | 88(65-125) |
| INRa | 1.26(1.15-1.43) |
| AST [U/L] a | 46.3(34.0-65.0) |
| ALT [U/L] a | 37.6(25.4-52.1) |
| Albumin [g/dL] | 33.2(30.2-36.8) |
| Creatinine [mg/dL] | 72(62.2-86.5) |
| Bilirubin [mg/dL] | 29.8(19.2-41.0) |
| AFP [ng/mL] a | 16.2(4.81-463.78) |
| <100 | 42(34.1%) |
| ≥100 | 81(65.9%) |
PVTT Portal vein tumor thrombosis, MELD Model of end stage liver disease, INR International normalised ratio, AST Aspartate aminotransferase, ALT Alanine transaminase, AFP Alpha fetoprotein, CI Confidence interval, IQR Interquartile range
aBarcelona Clinic Liver Cancer